A Fluorometric CYP19A1 (Aromatase) Activity Assay in Live Cells

David K. Heidary, Sarah M. Kriger, Austin C. Hachey, Edith C. Glazer

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Inhibition of estrogen synthesis is an integral component of the frontline pharmacologic therapy for the treatment of estrogen receptor positive cancers. However, there is currently no direct, high-throughput-ready assay for aromatase (also known as CYP19A1) that can be performed in live cells. Herein we present a cell-based assay that allows for multiplexed assessment of enzyme activity, protein half-life, cell viability, and identification of inhibitors with slow off-rates.

Original languageEnglish
Pages (from-to)2845-2850
Number of pages6
Issue number18
StatePublished - Sep 16 2021

Bibliographical note

Publisher Copyright:
© 2021 Wiley-VCH GmbH


  • Aromatase
  • Assay development
  • Breast cancer
  • CYP19A1
  • Cytochrome P450

ASJC Scopus subject areas

  • Drug Discovery
  • General Pharmacology, Toxicology and Pharmaceutics
  • Molecular Medicine
  • Biochemistry
  • Pharmacology
  • Organic Chemistry


Dive into the research topics of 'A Fluorometric CYP19A1 (Aromatase) Activity Assay in Live Cells'. Together they form a unique fingerprint.

Cite this